MARKET REPORT: UBS upgrade a reprieve for troubled AstraZeneca 0 21.11.2024 12:05 This is money Astrazeneca's share price fall was triggered by ongoing investigations in China and disappointing trial data for its cancer drug Dato-DXd. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
